Parathyroid hormone antagonists
CA 2040264 A1 · Owner: Kanmera, Tatsuhiko · Inventors: Nakao, Yoshihide; Kanmera, Tatsuhiko; Minegishi, Toshihiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Abstract of the Disclosure, Peptide derivatives of the following general formula (I):, ... (I), wherein AAA is deletion or Ser BBB is deletion or Glu, CCC, is deletion Ile, Phe, Leu, cyclohexylalanine, D-alle or Lys substituted at the ?-position by C6-C18 alkylcarbonyl group DDD is Gly or Gln, EEE is Leu, Nle or Phe FFF is Met, Leu, or Nle, GGG is Ala, Ser Leu, Asn, Asp or Gln, HHH is Leu, Glu or Lys III is His, Lys or Arg, JJJ is His, Lys or Arg Xaa is Ala modified at the carboxy terminal with an amino group, provided that CCC and DDD may independently be modified at the amino terminal by C2-C18 alkylcarbonyl group, and that EEE is not Leu when FFF is Met GGG is Asn, HHH is Leu, III and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 11, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 11, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 11, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.